Aura Biosciences (AURA) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aura Biosciences (AURA) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 12.2% versus a loss of 22.6%. Ginkgo Bioworks is the larger company by market cap ($752.9 million vs $669.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | DNA |
|---|---|---|
| Share price | $6.46 | $11.18 |
| Market cap | $669.93M | $752.95M |
| 1-day change | 0.00% | -2.52% |
| YTD return | +18.53% | +38.03% |
| 1-year return | +12.15% | -22.60% |
| 5-year return | — | -97.59% |
| EPS (TTM) | $-1.75 | $-5.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $18.22 |
| 52-week low | $4.73 | $5.37 |
| Distance from 52-week high | -32.25% | -38.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +156.97% | -37.39% |
| Average volume | 740.43K | 1.77M |
| Shares outstanding | 103.70M | 55.38M |
| Employees | 113 | 485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed DNA by 34.8 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
AURA vs DNA FAQ
Which is bigger, Aura Biosciences or Ginkgo Bioworks?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $752.95M compared with $669.93M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or DNA?
AURA returned +12.15% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Ginkgo Bioworks in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.